Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG2b antibody inhibitor against mouse PD-L1 (CD274/B7-H1), and the host is rat (Rat)[1]. Anti-Mouse PD-L1 Antibody can be used in animals to block PD-L1[2]. PD-L1 is one of the ligands of programmed death-1 (PD-1), the other is PD-L2. PD-1 is a member of the CD28 superfamily. Inhibition of the PD-1 pathway accelerates and enhances autoimmunity[3]. Inhibitors of PD-1 and its ligands, collectively known as immune checkpoint inhibitors, can enhance T cell responses[4]. PD-L1 is abundantly expressed in many mouse and human cancers and can be further upregulated under IFN-γ stimulation[5].
References:
[1] Stewart R, Morrow M, Hammond S A, et al. Identification and characterization of MEDI4736, an antagonistic anti–PD-L1 monoclonal antibody[J]. Cancer immunology research, 2015, 3(9): 1052-1062.
[2] Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases[J]. Cellular immunology, 2014, 290(1): 72-79.
[3] Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer[J]. Oncotarget, 2017, 8(2): 2171.
[4] Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer[J]. American journal of cancer research, 2020, 10(3): 727.
[5] He R, Yang X, Liu C, et al. Efficient control of chronic LCMV infection by a CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model[J]. Cellular & molecular immunology, 2018, 15(9): 815-826.